Public Employees Retirement System of Ohio Has $652,000 Stake in ChemoCentryx, Inc. (CCXI)

Public Employees Retirement System of Ohio continued to hold its position in ChemoCentryx, Inc. (NASDAQ:CCXI) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 69,613 shares of the biopharmaceutical company’s stock at the close of the second quarter. Public Employees Retirement System of Ohio owned about 0.14% of ChemoCentryx worth $652,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in CCXI. TIAA CREF Investment Management LLC increased its position in shares of ChemoCentryx by 37.5% in the first quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after acquiring an additional 35,049 shares during the period. Vanguard Group Inc. increased its position in shares of ChemoCentryx by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after acquiring an additional 47,475 shares during the period. Geode Capital Management LLC increased its position in shares of ChemoCentryx by 4.6% in the first quarter. Geode Capital Management LLC now owns 196,708 shares of the biopharmaceutical company’s stock valued at $1,432,000 after acquiring an additional 8,697 shares during the period. Renaissance Technologies LLC increased its position in shares of ChemoCentryx by 31.0% in the first quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock valued at $4,489,000 after acquiring an additional 146,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of ChemoCentryx by 35.9% in the first quarter. Goldman Sachs Group Inc. now owns 79,299 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 20,955 shares during the period. Hedge funds and other institutional investors own 49.22% of the company’s stock.

CCXI has been the topic of a number of analyst reports. ValuEngine cut shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $8.25.

ChemoCentryx, Inc. (NASDAQ:CCXI) opened at $7.49 on Friday. ChemoCentryx, Inc. has a 52-week low of $6.13 and a 52-week high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. research analysts expect that ChemoCentryx, Inc. will post -0.67 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.themarketsdaily.com/2017/11/12/public-employees-retirement-system-of-ohio-has-652000-stake-in-chemocentryx-inc-ccxi.html.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply